C. Wagner

发表

Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes.

B. Lanske, A. Wetterwald, W. Hoffstetter, 1996, Bone.

High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules

H. Rammensee, M. Garcia-Alai, C. Wagner, 2019, Science Immunology.

SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function

H. Rammensee, C. Wagner, N. Casadei, 2021, European journal of immunology.

Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy

Christopher E. Schraeder, Chih-Chiang Tsou, O. Schoor, 2022, Science Translational Medicine.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

B. Rini, S. Oudard, S. Crabb, 2016, The Lancet. Oncology.

Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.

S. Stevanović, M. Pfreundschuh, C. Wagner, 2005, Blood.

Actively personalized vaccination trial for newly diagnosed glioblastoma

J. Castle, H. Rammensee, S. Stevanović, 2018, Nature.

Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.

M. Pfreundschuh, C. Wagner, M. Wagner, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes

H. Rammensee, S. Stevanović, M. Pfreundschuh, 2004, Cancer Immunology, Immunotherapy.

Identification of an HLA‐DR‐restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM‐MEL‐40/SSX2

S. Stevanović, M. Pfreundschuh, C. Wagner, 2004, International journal of cancer.

Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

H. Rammensee, S. Stevanović, M. Pfreundschuh, 2003, Cancer immunity.

An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions

C. Wagner, A. Moritz, D. Maurer, 2023, Scientific Reports.

High-throughput peptide MHC affinity screening method for TCR ligands

C. Wagner, A. Moritz, D. Maurer, 2018 .

753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME

O. Schoor, C. Wagner, D. Maurer, 2022, Annals of Oncology.

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules

O. Schoor, C. Wagner, T. Weinschenk, 2019, Blood.

Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.

S. Stevanović, M. Pfreundschuh, C. Wagner, 2005, Blood.